Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Jacot

Showing results (101-110 of 196) with videos related to

Pageof 20
Sort By:
Molecular Oncology|January 8, 2014
Breast tumor PDXs are genetically plastic and correspond to a subset of aggressive cancers prone to relapseStanislas du Manoir, Béatrice Orsetti, Rui Bras-Gonçalves, et al.
British Journal of Cancer|June 9, 2018
Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkersSéverine Guiu, Caroline Mollevi, Céline Charon-Barra, et al.
Cancers|May 21, 2020
Co-Expression of Androgen Receptor and Cathepsin D Defines a Triple-Negative Breast Cancer Subgroup with Poorer Overall SurvivalHanane Mansouri, Lindsay B Alcaraz, Caroline Mollevi, et al.
Cancer Immunology, Immunotherapy : CII|November 8, 2023
Chronological interplay, clinical features, and treatments among patients with cancer and primary Sjögren's syndromePhiline Witkowski Durand Viel, Kim Henry, Jacques Morel, et al.
Journal of Pharmaceutical and Biomedical Analysis|July 6, 2020
Liquid chromatography-tandem mass spectrometric assay for the quantification of CDK4/6 inhibitors in human plasma in a clinical context of drug-drug interactionFanny Leenhardt, Matthieu Gracia, Catherine Perrin, et al.
Breast Cancer Research and Treatment|January 27, 2026
Second-line treatment strategy following CDK4/6 inhibitors for HR-positive and HER2-negative metastatic breast cancer patients: a multicentric, retrospective, observational studyOlivia Lavigne, François Poumeaud, Thibaut Reverdy, et al.
Contemporary Clinical Trials|October 8, 2013
Adapted physical activity and diet (APAD) during adjuvant breast cancer therapy: design and implementation of a prospective randomized controlled trialMarion Carayol, Gilles Romieu, Jean-Pierre Bleuse, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|August 19, 2020
Longitudinal analysis of health-related quality of life in cancer clinical trials: methods and interpretation of resultsCaroline Bascoul-Mollevi, Antoine Barbieri, Céline Bourgier, et al.
Breast Cancer Research and Treatment|May 12, 2016
Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastasesWilliam Jacot, Elvire Pons, Jean-Sébastien Frenel, et al.
British Journal of Cancer|January 30, 2023
Prognostic impact of extracranial disease control in HER2+ breast cancer-related brain metastasesMichele Bottosso, Gaia Griguolo, Léa Sinoquet, et al.
Pageof 20

Showing results (101-110 of 196) with videos related to

Sort By:
Pageof 20
Molecular Oncology|January 8, 2014
Breast tumor PDXs are genetically plastic and correspond to a subset of aggressive cancers prone to relapseStanislas du Manoir, Béatrice Orsetti, Rui Bras-Gonçalves, et al.
British Journal of Cancer|June 9, 2018
Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkersSéverine Guiu, Caroline Mollevi, Céline Charon-Barra, et al.
Cancers|May 21, 2020
Co-Expression of Androgen Receptor and Cathepsin D Defines a Triple-Negative Breast Cancer Subgroup with Poorer Overall SurvivalHanane Mansouri, Lindsay B Alcaraz, Caroline Mollevi, et al.
Cancer Immunology, Immunotherapy : CII|November 8, 2023
Chronological interplay, clinical features, and treatments among patients with cancer and primary Sjögren's syndromePhiline Witkowski Durand Viel, Kim Henry, Jacques Morel, et al.
Journal of Pharmaceutical and Biomedical Analysis|July 6, 2020
Liquid chromatography-tandem mass spectrometric assay for the quantification of CDK4/6 inhibitors in human plasma in a clinical context of drug-drug interactionFanny Leenhardt, Matthieu Gracia, Catherine Perrin, et al.
Breast Cancer Research and Treatment|January 27, 2026
Second-line treatment strategy following CDK4/6 inhibitors for HR-positive and HER2-negative metastatic breast cancer patients: a multicentric, retrospective, observational studyOlivia Lavigne, François Poumeaud, Thibaut Reverdy, et al.
Contemporary Clinical Trials|October 8, 2013
Adapted physical activity and diet (APAD) during adjuvant breast cancer therapy: design and implementation of a prospective randomized controlled trialMarion Carayol, Gilles Romieu, Jean-Pierre Bleuse, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|August 19, 2020
Longitudinal analysis of health-related quality of life in cancer clinical trials: methods and interpretation of resultsCaroline Bascoul-Mollevi, Antoine Barbieri, Céline Bourgier, et al.
Breast Cancer Research and Treatment|May 12, 2016
Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastasesWilliam Jacot, Elvire Pons, Jean-Sébastien Frenel, et al.
British Journal of Cancer|January 30, 2023
Prognostic impact of extracranial disease control in HER2+ breast cancer-related brain metastasesMichele Bottosso, Gaia Griguolo, Léa Sinoquet, et al.
Pageof 20